Join Our Mailing List:
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
Featured Events
View All Events
Saul Priceman, Ph.D.
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Cancer Immunotherapy, T-Cells, Tumor Immunology
Award Year: 2017

Career Summary: Dr. Priceman is an Assistant Research Professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing Chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate, and pancreatic cancer. Dr. Priceman received his BS in Microbiology at the University of California, Santa Barbara; and his PhD in Molecular and Medical Pharmacology at the University of California, Los Angeles.
Dr. Priceman is a Principal Investigator on a Prostate Cancer Foundation Young Investigator award, a co-Principal Investigator on a Prostate Cancer Foundation Challenge Award, and a Principal Investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR T therapy for metastatic breast cancers, and working with his team optimizing new CAR T cell therapies for various other solid cancers. Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.
Description of research performed: The overall goal of this proposal is to develop a breast cancer-specific HER2-CAR T cell to preferentially target over-expressed and/or amplified HER2 expressing tumors using preclinical models that faithfully recapitulate systemic metastases observed in breast cancer patients. These studies will ultimately lead to an IND submission for testing this therapy in clinical trials, with potential to significantly improve outcomes for patients battling this disease


STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2017 STOP CANCER. All Rights Reserved. | Privacy Policy